Tiziana Life Sciences Raises $8.8 Million in Oversubscribed Direct Offering to Fund Phase 2 Trials

The latest update is out from Tiziana Life Sciences ( (TLSA) ).

On January 16, 2026, Tiziana Life Sciences closed an oversubscribed, company-led registered direct offering of 7,040,000 ordinary shares at $1.25 per share, raising $8.8 million in gross proceeds from senior management and existing shareholders without the use of an underwriter or placement agent. Each share includes a warrant exercisable at $1.50 per share until July 16, 2026, potentially adding about $10.56 million in further funding; the chief executive officer and the executive chairman significantly increased their holdings in the process, and the company said the proceeds will allow it to complete its Phase 2 clinical trials in non-active secondary progressive multiple sclerosis and multiple system atrophy and deliver top-line data readouts, a key step in advancing its lead intranasal foralumab program.

The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.

More about Tiziana Life Sciences

Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on developing breakthrough immunotherapy treatments using alternative drug delivery technologies, particularly intranasal administration. Its lead product candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development and targets neuroinflammatory and neurodegenerative diseases, including non-active secondary progressive multiple sclerosis, supported by a portfolio of patented and pending technologies for broader pipeline applications.

Average Trading Volume: 285,454

Technical Sentiment Signal: Hold

Current Market Cap: $174.7M

See more data about TLSA stock on TipRanks’ Stock Analysis page.